Post-marketing surveillance reports indicate that TNF-blockers such as infliximab, etanercept, adalimumab, certolizumab, and golimumab increase the risk of haematological and other cancers and psoriasis in children, adolescents, and adults.
More at www.docguide.com and in the next Doctor's Guide Weekly Edition.
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου